New Policy Review: Defining the quality of #interdisciplinary care for patients with #brainmetastases: modified Delphi panel recommendations thelancet.com/journals/lanon…

New Review: The oncological role of resection in newly diagnosed diffuse #adult-type #glioma defined by the WHO 2021 classification: a Review by the RANO resect group thelancet.com/journals/lanon…

New Policy Review: Translating the #theranostic concept to #neurooncology: disrupting barriers thelancet.com/journals/lanon…

In our new issue - Comment: Contextualising #legal and #ethical conundrums of #artificialintelligence in #oncology thelancet.com/journals/lanon…

See our article on the Right To Be Forgotten published today in the September issue of The Lancet Oncology Union for International #CancerControl Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe - The Lancet Oncology thelancet.com/journals/lanon…

Online First: Policy Review: #Fertility-sparing treatment and follow-up in patients with #cervicalcancer, #ovariancancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and European Society of Gynaecological Endoscopy thelancet.com/journals/lanon…

New in The Lancet Gastroenterology & Hepatology - dose reduction strategies for pancreatic cancer treatment A summary 👉 linkedin.com/posts/rob-brie… #GITwitter #OncTwitter #PancSM

London Global Cancer Week 2024 is coming soon! Join us from November 11-15 for a week of impactful discussions aimed at improving global cancer outcomes. Review the schedule today and plan your participation. #LGCW2024 #GlobalHealth #CancerAwareness #LondonGlobalCancerWeek

News: World's first lung #cancervaccine trial launched in the UK thelancet.com/journals/lanon…

News: Continued suboptimal #HPVvaccine coverage in the #USA thelancet.com/journals/lanon…

✅@RadOnc_Journal & @TheLancetOncology are teaming up! Submit your clinical trials for a chance to present at a special joint session and get published in one of these top journals. Pierre Blanchard, MD, David Collingridge 📅: 20 Nov 2024 ℹ️ bit.ly/47aASOa #ESTRO25 #radonc

ICYMI – Adaptive #radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell #lungcancer, according to [18F]FDG-PET uptake (RTEP7–IFCT-1402): a multicentre, randomised, controlled, phase 2 trial thelancet.com/journals/lanon…

Look at this opportunity for simultaneous oral presentation at #ESTRO25 publication in the Green Journal (Radiotherapy & Oncology) or The Lancet Oncology and prepare your clinical trial paper!

Now in the Sept issue: Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial #GIST #cancer thelancet.com/journals/lanon…